1. Home
  2. HEQ vs NERV Comparison

HEQ vs NERV Comparison

Compare HEQ & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HEQ

John Hancock Hedged Equity & Income Fund of Beneficial Interest

HOLD

Current Price

$11.27

Market Cap

139.0M

Sector

Finance

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$2.30

Market Cap

166.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HEQ
NERV
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.0M
166.4M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
HEQ
NERV
Price
$11.27
$2.30
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $10.33
AVG Volume (30 Days)
22.4K
★ 105.4K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.50
$2.24
52 Week High
$12.00
$8.80

Technical Indicators

Market Signals
Indicator
HEQ
NERV
Relative Strength Index (RSI) 46.95 27.35
Support Level $10.88 N/A
Resistance Level $11.63 $5.69
Average True Range (ATR) 0.19 0.26
MACD 0.03 -0.02
Stochastic Oscillator 51.42 4.83

Price Performance

Historical Comparison
HEQ
NERV

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return, with a focus on current income and gains, and to include long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: